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Abstract
Background: Plasmodium falciparum genetic diversity and multiplicity of infection (MOI) are parasite features that
have been suggested to influence the acquisition of protective immunity against malaria. This study sought to
assess the relationship between MOI and parasite density (PD) in malaria patients living in the Central Region of
Ghana and to determine whether naturally occurring antibody levels against P. falciparum GLURP (PF3D7_1035300)
and MSP3 (PF3D7_1035400) antigens are associated with decreased parasite load.
Methods: Dried filter paper blood blots were obtained from children and adults diagnosed with uncomplicated P.
falciparum malaria. Microscopy was used to estimate P. falciparum parasite density and polymerase chain reaction
(PCR) amplification of the polymorphic regions of msp1 (PF3D7_0930300) and msp2 (PF3D7_0206800) was used for
parasite genotyping and MOI determination. ELISA was used to measure the serum IgG concentration of R0
fragment of GLURP (GLURP(R0)) and MSP3 antibodies.
Results: All 115 samples were positive for P. falciparum by PCR using either the msp1 or msp2 genotyping primer
sets. The most prevalent msp1 and msp2 alleles were KI and 3D7, respectively. The geometric mean (GM) for MOI
determined by both msp1 and msp2 genotyping was 1.3 for the entire population and was generally higher in
children than in adults. Seropositivity was estimated at 67 and 63% for GLURP(R0) and MSP3 antibodies,
respectively, and antibody titers were negatively correlated with parasite density.
Conclusions: The negative correlation between naturally occurring GLURP(R0) and MSP3 antibody levels and
parasite density observed in this study suggest that augmenting the antibody response with the GMZ2 vaccine
could enhance protection in the Central Region of Ghana.
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Background
The 2015 annual report of the Ghana National Malaria
Control Program reported that 39.2% of all the Out-
patient Department cases recorded in the Central Region
were due to malaria [1]. This 44.5% increase in reported
malaria cases from 2014 to 2015 [1] suggests that
malaria still remains a disease of public health concern
despite the enormous advances in interventions to con-
trol the disease. The enormous genetic diversity found
in the P. falciparum parasites is likely to complicate dis-
ease control. This diversity within P. falciparum has
served as a key survival mechanism for the parasite, as it
allows for immune evasion as well as drug resistance [2].
Major malaria treatment regimens such as chloroquine
[3] have already failed and tolerance and resistance to ar-
temisinin combination therapy has been reported in
some malaria endemic countries [4, 5]. Specific P. falcip-
arum parasite genotypes, such as PfEMP1-DBL1α, have
also been implicated with severe malaria [6] and the
CAMP(C-) genotype of EBA 175 associated with severe
malaria and fatal outcome [7], again suggesting parasite
diversity plays an important role in the clinical manifest-
ation and pathology of malaria [8]. Merozoite surface
antigens of the parasite such as MSP1 and MSP2 are ex-
posed directly to immune pressure and found to be
highly polymorphic. Plasmodium falciparum merozoite
surface proteins 1 (MSP1: PF3D7_0930300) and 2
(MSP2: PF3D7_0206800) are widely used in the field for
determining parasite diversity and multiplicity of infec-
tion. The msp1 gene has been divided into three allelic
families namely K1, MAD20, and RO33 type based on
the diversity within the Block 2 region of the gene se-
quence [9]. The msp2 gene is dimorphic [10] based
on diversity with the Block 3 region of its gene se-
quence and it is classified as being in the FC27 or
3D7 allele family. These merozoite surface antigens
have proven to be vital tools in characterizing P. fal-
ciparum parasites [11].
Infections of P. falciparum have also been implicated
in the maintenance of strain-specific anti-merozoite
antibodies. An increase in the number of FC27 alleles in
an infection has been associated with increased antibody
titres to the MSP2-Dd2 (FC27 family allele) but not
MSP2-Ch150/9 (3D7 family allele) antigen [12]. To
cover both 3D7 and FC27 allele families, a MSP1-C1
combination vaccine containing 3D7 and FC27 alleles
was developed, but unfortunately it showed unaccept-
able reactogenicity limiting further analysis [13]. Multi-
clonal infections, consisting of diverse concurrent
clones, could be advantageous to the host as it enables
the acquisition of antibodies to genetically diverse para-
sites (increased breadth of antibodies) as has been shown
in asymptomatic infections [11, 14]. It has also been re-
ported to reduce the risk of clinical illness during a
subsequent infection with a clonally similar parasite [15,
16], as antibody titers maintained by multiclonal asypto-
matic infection may be more likely to arrest the growth
of newly acquired, but clonally similar parasites [17].
In addition to merozoite surface proteins, parasite an-
tigens released when mature schizont-infected erythro-
cytes burst are also exposed to host immune defenses
and one of these, GLURP(R0), is included in a current
vaccine candidate GMZ2 [18–20]. GMZ2 is a chimeric
malaria vaccine composed of the R0 fragment of
GLURP(R0) fused to MSP3 [21] and is undergoing vac-
cine trials in a number of African countries including
Ghana [22]. Antibodies against both GLURP(R0) and
MSP3 have been implicated in the acquisition of protect-
ive immunity to malaria [23]. The present study was de-
signed to identify possible associations between the
natural immune response to GLURP(R0) and MSP3,
parasite density and multiplicity of infection in the forest
zone of the Central Region of Ghana.
Methods
Study site and sample acquisition
Peripheral whole blood samples used for dried filter
paper blood blots, thick and thin blood smears and har-
vesting of serum were collected from each participant as
part of a larger study from three districts in the Central
Region of Ghana [24]. The hemoglobin concentrations
of the blood samples were measured directly using auto-
mated blood analyzers in the various study hospitals.
The study was conducted a district hospital located in
Abura Dunkwa, Twifo Praso and Assin Fosu in the Cen-
tral Region of Ghana (Fig. 1). All the three study sites
are in the forest zone of Ghana and share common peak
(April-September) and off peak (November-March) mal-
aria seasons. In 2013, the incidence of clinical malaria
ranged between 11 and 15% in the three sites [25, 26].
Extraction of parasite DNA
Two 3 mm punches (discs) of dried blood blots from the
filter paper were used for gDNA extraction using the
Saponin-Chelex extraction method [27]. Briefly, discs for
each sample were incubated in 1120 μl of a 0.5% sap-
onin/phosphate buffered saline (PBS) solution overnight
at room temperature on a shaking incubator. After incu-
bation, the discs were washed twice with 1 ml PBS,
followed by centrifugation at 10,000× g. Subsequently,
150 μl of a 6% Chelex-100 (Sigma-Aldrich, Missouri,
USA) in DNase/RNase free water was added to the discs
and incubated for 5 min at 95 °C. After a final high-
speed centrifugation, the supernatant containing the
gDNA was either used immediately for the genotyping
PCR amplification reactions or stored at - 20 °C.
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Molecular identification and genotyping
To distinguish between the three major msp1 allelic
families (K1, MAD 20, and RO33) and the two msp2
allelic families (FC27 and 3D7), nested PCR was
performed using family-specific primers [28] shown in
Table 1. The outer PCR reaction mixture contained
200 nM dNTP, 2 mM MgCl2, 133 nM of each forward
and reverse primer, 0.5 units of One Taq DNA polymer-
ase (New England BioLab, MA, USA) and 4 μl (about
0.25 μl of whole blood) of genomic DNA (gDNA) tem-
plate. The inner nested reaction mixture contained
200 nM dNTP, 1.8 mM MgCl2, 200 nM of each forward
and reverse primer and 0.5 unit of One Taq DNA poly-
merase supplemented with 0.5 μl of the primary PCR
product. The cycling parameters for the nested PCR
consisted of an initial denaturation at 94 °C for 3 min,
followed by 30 cycles at 94 °C for 1 min; 50–59 °C (opti-
mized for each primer pair) for 35 s, and 68 °C for
2 min 30 s; with a final extension at 68 °C for 5 min.
The PCR reactions were all run on a Biometra TAdvance
thermal cycler (Göttingen, Germany). Positive gDNA
controls for each allelic family (3D7 strain - alleles, msp2
3D7/msp1 KI; K1 strain - alleles, msp1 KI/msp2 FC27;
HB3 strain - alleles msp1 MAD20/msp2 FC27 and RO33
strain - alleles, msp1 RO33/msp2 3D7 were from MR4)
and no template negative control were included in each
set of PCR reactions. PCR products were separated on
2% ethidium bromide-stained agarose gels and visualized
under UV illumination.
Multiplicity of infection
The number of concurrent infecting genotypes con-
tained in each sample, which represents the multiplicity
of infection (MOI) for that sample, was calculated as the
highest number of alleles obtained in the sample after ei-
ther msp1 or msp2 genotype reactions. Samples with
more than one PCR fragment per marker (infecting
genotype) were considered as containing multiclonal in-
fections, whereas samples with only one infecting geno-
type for either marker were considered as clonal with
respect to that marker. The geometric mean (GM) of
MOI for both msp1 and msp2 genotyping was calculated
by determining the GM for the sum of the MOI
Fig. 1 Map of Ghana showing study sites. Samples were collected from the hospitals marked H located in Twifo Praso, Assin Fosu and Abura
Dunkwa in the Central Region of Ghana. Twifo Praso is the district capital of Twifo-Ati Morkwa district, Assin Fosu in the district capital of Assin
North Municipality and Abura Dunkwa is the district capital of Abura-Asebu Kwaman Kese
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identified for each sample divided by the total number
of samples positive for the same marker.
GLURP(R0) and MSP3 ELISA
One hundred microliters of affinity purified GLURP(R0)
[19, 29] or MSP3 [19, 29] in PBS at 1 μg/ml was used to
coat 80 wells of a NUNC maxisorp 96-well ELISA plate
overnight at 4 °C. The remaining 16 wells were filled
with 100 μl of purified human polyclonal IgG (PB055,
The Binding Site) serially titrated to serve as standards.
The plates were subsequently washed four times with 1×
PBS with 0.05% Tween 20 (1× PBST), blocked with
150 μl of 3% skimmed milk in 1× PBST, washed twice
and incubated for 1 h with 100 μl of test serum or a pool
of negative control serum from donors living in non-
endemic countries, diluted 1:200 in 1% skimmed milk in
1× PBST. Subsequently, after four 1× PBST washes,
bound IgG were probed with polyclonal rabbit anti-
human IgG-horseradish peroxidase (1:3000 dilution in
1% skimmed milk in 1× PBST) for 1 h. Plates were then
washed four times as described above and the bound
conjugate detected by incubating with 50 μl of tetra-
methylbenzidine substrate and stopping the reaction
with 50 μl of 0.2 M sulphuric acid. ELx808 Absorbance
Reader (BioTek, VT, USA) was used to read the ODs of
each sample.
Data analysis
Data were entered into Excel, converted to concentra-
tions using ADAMSEL (Ed Remarque) and analyzed
using GraphPad Prism v7 and SPSS v.22 (IBM). The fre-
quency of each msp1 and msp2 allelic family as well as
the geometric mean and corresponding 95% confidence
interval were calculated using frequency distribution in
GraphPad Prism. The correlation between age and PD,
GLURP(R0) and MSP3 IgG concentrations was per-
formed using GraphPad Prism. SPSS descriptive statis-
tics (cross tabs) was used to determine the descriptive
statistics for the participants per study site (Additional
file 1: Table S1). SPSS nonparametric tests (independent
samples) were used to determine the association be-
tween IgG concentrations and antibody seropositivity
with MOI and parasite density and also to draw graphs
showing the relationship between PD, Age and IgG sero-
positivity (Additional file 2: Figure S1). Statistical signifi-
cance was defined as P value ≤ 0.05 unless otherwise
stated. Using an estimate of 8000 white blood cells/μl of
blood, the number of asexual blood stage parasites was
determined for 200 WBCs and multiplied by 40.
Results
The study population included 115 symptomatic malaria
patients, 47 (41%) were from Assin Fosu, 36 (31%) from
Twifo Praso and 32 (28%) from Abura Dunkwa (Fig. 1).
The geometric mean (GM) age of the study population
was 6.37 (95% CI: 5.1–7.97) years. The GM of the P. fal-
ciparum parasite density (PD) was 7715 (95% CI: 5719–
10,408) parasites/μl blood with a standard error of the
mean of 3230. The GM of the hemoglobin concentra-
tions within the population was 9.4 (95% CI: 9.0–9.8)
(Table 2). Due to the similarities in demographic features
between the three study sites (Additional file 1: Table
S1), data analysis was performed on the total sample set
without differentiating according to study site. Although
children had relatively higher parasite densities than the
Table 1 msp1 and msp2 genotyping primers
Marker Primer name Primer sequence (5′-3′) Annealing temperature (°C)
msp1
Primary M1- OF CTAGAAGCTTTAGAAGATGCAGTATTG 54
M1- OR CTTAAATAGTATTCTAATTCAAGTGGATCA
K1 M1- KF AAATGAAGAAGAAATTACTACAAAAGGTGC 59
M1- KR GCTTGCATCAGCTGGAGGGCTTGCACCAGA
MAD 20 M1- MF AAATGAAGGAACAAGTGGAACAGCTGTTAC 59
M1- MR ATCTGAAGGATTTGTACGTCTTGAATTACC
RO33 M1- RF TAAAGGATGGAGCAAATACTCAAGTTGTTG 59
MI- RR CAAGTAATTTTGAACTCATGTTTTAAATCAGCGTA
msp2
Primary M2- OF ATGAAGGTAATTAAAACATTGTCTATTATA 54
M2- OR CTTTGTTACCATCGGTACATTCTT
3D7/FC27- F S1fw GCTTATAATATGAGTATAAGGAGAA 50
FC27- R M5rev GCATTGCCAGAACTTGAA
3D7 - R N5rev CTGAAGAGGTACTGGTAGA
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adults, the correlation was not significant (Spearman’s
r = -0.949, P = 0.35; Additional file 3: Figure S3).
Parasite genotyping
Out of the 115 samples collected 97 (84.3%) and 99
(86.1%) were successfully amplified for msp1 and msp2
genes, respectively. From the 97 samples with positive
PCR products from the msp1 PCR amplifications, a total
of 126 PCR fragments were obtained. The overall fre-
quency of the K1 allele was the highest, 67 (53.2%),
followed by MAD20, 38 (30.1%), and RO33 at 33
(26.2%). Similarly, from the 99 samples that yielded posi-
tive PCR fragments for the msp2 gene, a total of 52 sam-
ples contained parasites belonging to the FC27 allele
family, of which 10 (19.2%) harbored double infections
and thus resulted in a total of 62 PCR fragments (42
samples with single and 10 with double PCR fragments,
42.2%). Seventy-six samples contained parasites belong-
ing to the 3D7 allele family, with 9/76 (11.8%) of the
samples harboring two distinct parasite populations
thereby producing a total frequency of 85 PCR frag-
ments (57.8%) (Fig. 2). In total, 147 PCR fragments (62
FC alleles and 85 3D7 alleles) were obtained from the
msp2 targeted PCR amplifications from 99 samples.
Multiplicity of infection
Combining the number of independent PCR fragments
obtained for the three families, specific PCR amplifica-
tions for msp1 revealed that 62 samples produced a sin-
gle PCR fragment, two PCR fragments were obtained
from 29 samples and 6 samples produced three different
PCR fragments (Fig. 3). The GM for MOI obtained after
msp1 genotyping was 1.32 (95% CI: 1.22–1.42) (Additional
file 1: Table S1). Combining the total number of PCR frag-
ments obtained from a sample after msp2 genotyping re-
vealed that 64 samples contained a single PCR fragment,
24 samples contained two different fragments, 9 samples
contained 3 PCR fragments and 2 samples contained 4
PCR fragments (Fig. 3). The GM for MOI obtained after
msp2 genotyping was 1.34 (95% CI: 1.24–1.46) (Additional
file 1: Table S1). MOI determined by msp2 genotyping
was significantly negatively correlated with age (Spear-
man’s r = -0.2103, P = 0.044), but positively correlated
with PD (Spearman’s r = 0.2290, P = 0.023). The GM of
MOI determined by both msp1 and msp2 genotyping gen-
erally decreased with increasing age (Fig. 4a, b). The over-
all MOI in each sample was taken as the highest MOI
predicted by either msp1 or msp2 genotyping. The GM
for the overall MOI in this study population was 1.43
(95% CI: 1.32–1.55).
IgG concentrations of GLURP(R0) and MSP3 antibodies
IgG concentrations of antibodies against MSP3 were
significantly higher than those against GLURP(R0)
(Spearman’s r = 0.588, P < 0.0001). A significantly posi-
tive correlation was found to exist between age and IgG
Table 2 Background characteristics of study participants
Age (years) HB (g/dl) PD/μl
Count (n) 102 99 112
Minimum n 0.5 4.4 40
Maximum n 35 13.6 184,600
Geometric mean (GM) 6.369 9.352 7715
Lower 95% CI of GM 5.095 8.967 5719
Upper 95% CI of GM 7.962 9.754 10,408
Abbreviations: n total number of samples analyzed, HB (g/dl) hemoglobin
concentration, PD/μl parasite density
Fig. 2 Distribution of msp1 and msp2 alleles. A graphical representation of data obtained from agarose gel electrophoresis of the allele-specific
(msp1 and msp2 family) genotyping reactions. The number of samples that yielded one msp1 allele (black checked) or one (dark grey) or two
(light grey) msp2 alleles in PCR reactions with the indicated allele-specific primer set are plotted
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concentrations of both GLURP(R0) (Spearman’s
r = 0.454, P < 0.0001) and MSP3 (Spearman’s r = 0.494,
P < 0.0001) antibodies (Table 3, Fig. 5).
In contrast, PD was negatively correlated with MSP3
(Spearman’s r = -0.1944, P < 0.0502) as well as
GLURP(R0) (Spearman’s r = -0.2461, P < 0.015) IgG con-
centrations. Seropositivity in this study was defined as
serum antibody levels higher than the cutoff value, which
is the mean of the antibody concentrations of the negative
control plus 2 standard deviations. Applying the cutoff of
589 ng/μl and 3249 ng/μl for GLURP(R0) and MSP3, re-
spectively; 67% of the participants were seropositive for
GLURP(R0) and 63% for MSP3.
Multiplicity of infection and GLURP(R0) and MSP3
antibody concentrations
Although the GM of the MOI in this study was relatively
low, a significant association was identified with IgG con-
centrations of MSP3 (Independent-Samples Median
Test, P = 0.008), but not GLURP(R0) antibodies
(Independent-Samples Median Test, P = 0.053), across the
varying msp2 MOI categories. No significant association
was found between either GLURP(R0) (Independent-Sam-
ples Median Test, P = 0.702) or MSP3 (Independent-Sam-
ples Median Test, P = 0.343) IgG concentrations and
MOI determined by msp1 genotyping.
Discussion
This study accessed the genetic diversity and multiplicity
of P. falciparum infection as well as antibody reponses
to two asexual malaria vaccine candidate antigens
(GLURP(R0) and MSP3) in a cohort of patients presenting
to the hospital with uncomplicated malaria. The geometric
mean (GM) of the parasite density (PD) in the study partic-
ipants was 7715 parasites/μl (Additional file 1: Table S1).
This was much lower than previously reported,
(20,319/μl) for children with malaria in a different
community within the same Region of Ghana [28]. Al-
though there was a general decrease in PD with in-
creasing age, no significant difference in PD among
Fig. 3 Multiplicity of infection for msp1 and msp2. The number of samples are indicated that contained a total of one, two, three or four msp1
alleles (black) or msp2 alleles (light grey) when the results of all the genotyping reactions using the msp1 K1, MAD20 or RO33 (black) or msp2
FC27 or 3D7 (dark grey) allele-specific primer sets were combined
Fig. 4 Geometric mean of MOI determined by msp 1 (a) and msp 2 (b) genotyping. Study participants were grouped into young children
(0–5 yrs), older children (6–17 yrs) and adults (> 17 yrs). The geometric mean of the total number of PCR fragments obtained in each group per
marker (msp1 or msp2), which also represents the geometric mean of the MOI, is plotted with the 95% confidence interval
Amoah et al. Parasites & Vectors  (2017) 10:395 Page 6 of 9
the study population was observed (Additional file 3:
Figure S3) which is contrary to other reports, such as
one from a study conducted in Kenya where young
children (5–10 years) carried significantly higher para-
site densities than older children (10–15 years) [30].
The most prevalent msp1 allelic family was the KI al-
lele (Fig. 2); this finding is consistent with our previous
study [28] conducted along the coast of the Central Re-
gion of Ghana as well as other studies on asymptomatic
and uncomplicated malaria patients in Cameroon [31]
and Ethiopia [32]. However, this study identified the 3D7
allele of msp2 as the most prevalent (Fig. 2), which was
contrary to our previous study [28] but similar to other
studies conducted in Ghana [33, 34].
The presence of concurrent P. falciparum parasite infec-
tions in this study population was low (Fig. 3), with a GM
for MOI as 1.3 (Additional file 1: Table S1) indicating only
a minority of patients being infected with multiple para-
sites. A previous study conducted in Southern Ghana in
2013 identified the GM for MOI of malaria patients as 1.3
[34]. However, our previous study conducted along the
coast of the Central Region of Ghana reported a relatively
higher geometric mean for MOI, 1.92 and 1.88 for MOI
determined by msp1 and msp2, respectively, in children
with uncomplicated malaria [28].
There was no significant difference in MOI deter-
mined by either msp1 or msp2 genotyping among the
three age groups studied (Fig. 4), which is consistent
with recent reports from Sudan [35], Uganda [36] and
Ethiopia [32]. Although there was a significant relation-
ship between MOI and parasite density which was not
observed in the Ethiopian study [32]. The MOI analysis
might have been more sensitive if pyrosequencing [37]
or capillary electrophoresis [38] had been used for the
msp1 and msp2 genotyping as these techniques are able
to distinguish between all possible different strains con-
tained within a single PCR amplicon.
This study shows higher IgG levels against MSP3 than
GLURP(R0) (Fig. 5), previously reported [39], however, IgG
antibody levels for GLURP(R0) measured in children from
Dodowa in the Greater Accra Region of Ghana in 2002
were higher than those for MSP3 [19]. This study reports
increased IgG levels against GLURP(R0) and MSP3 with in-
creasing age, which is similar to the previous report from
Dodowa [19]. The overall seroprevalence of 67% for
GLURP(R0) to 63% for MSP3 is also is similar to other
studies which ranged from 58.6% [39] to 65% [40]. The re-
sults from this study also indicate that high antibody levels
against GLURP(R0) and MSP3 are associated with lower
parasite density [41–43] and likely protection from disease.
Conclusions
The negative correlation between naturally occurring
GLURP(R0) and MSP3 antibody levels and parasite
Table 3 Correlation between age and PD, R0 IgG and MSP3 IgG concentrations
Age (yrs) vs PD Age (yrs) vs RO Age (yrs) vs MSP3
Spearman’s r -0.09489 0.4546 0.4941
95% confidence interval -0.2923 – 0.1103 0.2675 – 0.6087 0.3164 – 0.6384
P-value (two-tailed) 0.3501 < 0.0001 < 0.0001
Number of XY pairs 99 90 92
Fig. 5 IgG concentrations of GLURP(R0) (a) MSP3 (b) and antibodies across the various age groups. A graphical represtation of the total IgG
concentration (ng/ml) against GLURP(R0) (a) and MSP3 (b) in young children (0–5 yrs), older children (6–17 yrs) and adults (> 17 yrs). For each
age group the GM with the 95% confidence interval of the antibody concentrations are indicated
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density observed in this study suggest that augmenting
the antibody response with the GMZ2 vaccine, or other
vaccines that stimulates an increased production of anti-
bodies against GLURP(R0) and MSP3, could enhance
protection in the Central Region of Ghana. However,
diversity in candidate vaccine antigens could influence
the effect and will have to be monitored prior to and
during vaccine trials.
Additional files
Additional file 1: Table S1. Demographic features of the study
participants per site and overall. Abbreviations: n, number of patients; GM,
geometric mean; 95% CI, 95% confidence interval of the GM. Numbers in
parenthesis represent the total number of patients. (DOCX 79 kb)
Additional file 2: Figure S1. Relationship between MSP3 (a) and
GLURP(R0) (b) IgG seropositivity and Age (left y-axis) and PD (right y-axis).
SPSS derived graphs showing the relationship between the mean Age
(left y-axis) and PD/μl blood (right y-axis, log scale) of the study partici-
pants and IgG seropositivity to GLURP(R0) and MSP3. Error bars represent
the standard error of the mean. 0, seronegative; 1, seropositive for MSP3
(a) and GLURP(R0) (b) antibodies. (DOCX 278 kb)
Additional file 3: Figure S2. A graphical representation of the
correlation between log transformed PD and patient age (a) and
stratified patient age (b). (DOCX 131 kb)
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